
Why Employers Choose the DrugWipe 6S Saliva Drug Testing Kit
If you're looking for a reliable testing kit that meets national standards and delivers consistent results, here's why the DrugWipe 6S Saliva Drug Testing Kit deserves your attention.
Let's start with the basics. The DrugWipe 6S Saliva Drug test offers: Fast results – Get answers in just 8 minutes No lab tools required – All results are visually read Zero saliva handling – More hygienic and less invasive Point-of-incident ready – Ideal for on-site or random testing AS/NZS 4760:2019 compliant – Fully meets Australian standards
The test detects six commonly abused drug groups: Methamphetamines (including ecstasy)
With broad detection coverage and fast results, this kit helps you act quickly when workplace safety is at risk.
In high-risk environments like construction or mining, time matters most. The DrugWipe 6S Saliva Drug Testing Kit gives you quick answers when every second counts—helping you take the right action at the right time.
In Australia, workplace drug testing must be both effective and legally defensible.
That's why using a kit certified to AS/NZS 4760:2019 is so important. The DrugWipe 6S Saliva Drug Testing Kit from Australia Drug Testing meets this exact standard.
What does that mean for you? Accurate test performance Credible results in legal or HR matters Confidence in compliance during audits or reviews
When you use a testing device that meets the national benchmark, you can feel confident you're doing it right.
Using the DrugWipe 6S Saliva Drug test is straightforward. Here's a simplified version of the process: Open the kit and check the three weak blue control lines. Instruct the donor to move their tongue around their mouth. Hand them the blue sample collector and have them wipe it down their tongue once. Make sure the sample pads change from pink to yellow. Reattach the collector to the detection unit and press until it clicks. Crack the buffer ampoule by pressing the 'PRESS' mark. Set the kit upright for 10 seconds, then lay it flat. Wait 8 minutes—then read the result.
It's that simple. No mess. No guesswork.
While reading the results, here's what to look for: Negative result = Only control lines appear Non-negative result = A control line plus any faint or bold test line appears
If drugs are detected, you can follow up with a confirmatory lab test.
Each method has its place, but here's how they compare:
Saliva Testing (like DrugWipe 6S): Detects recent drug use (2–4 hours) Best for on-the-spot impairment checks Less invasive and faster to administer
Urine Testing: Detects drug use over a longer time More suitable for pre-employment screening Often more cost-effective for large batches
If your priority is identifying recent drug use and impairment, saliva testing is the better option—and the DrugWipe 6S Saliva Drug Testing Kit is built for it.
Need alternative options? Australia Drug Testing also offers:
First Step Oral Fluid Drug Screen Device Verified to AS/NZS 4760:2019 Includes saturation indicator Easy to use and non-invasive
First Sign Saliva Drug Testing Kit Screens for Δ9 THC (not just metabolites) Quick, 1-step test with swab and test in one Results in under 5 minutes
While these are great choices too, the DrugWipe 6S Saliva Drug test remains a robust option for on-site testing in many Australian workplaces.
If you're serious about maintaining a safe, drug-free work environment, you need a test that delivers reliable results—fast. The DrugWipe 6S Saliva Drug Testing Kit offers everything you need: compliance, convenience, and confidence.
Ready to upgrade your workplace drug tests? Browse the DrugWipe 6S Saliva Drug Testing Kit and other certified solutions at Australia Drug Testing—and make safety your workplace standard.
TIME BUSINESS NEWS
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
2 days ago
- Bloomberg
FDA Investigates Death of Boy Who Got Sarepta's Gene Therapy
US regulators said they are investigating the death of an 8-year-old boy who received a gene therapy from Sarepta Therapeutics Inc. The death occurred on June 7, according to a statement from the US Food and Drug Administration.


Newsweek
2 days ago
- Newsweek
Doctor Raises Concerns Over Medical Cannabis Use With Cancer Treatment
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Despite its growing popularity among cancer patients for managing symptoms like nausea, pain and reduced appetite, a new study has warned that the use of medicinal cannabis could make immunotherapy less effective. This is the warning of Australian medical cannabis advocate Dr. Ben Jansen, whose newly-published review paper poses the question: "Are cannabinoids with cancer immunotherapy contributing to early death?" "As both a physician involved in the medicinal cannabis industry and an advocate for patient care, I find the discussion and patient informed consent around this interaction critical," Jansen wrote in his study. "Three key studies on this topic offer preliminary data suggesting a potential reduction in immunotherapy efficacy from cannabis use," he continued. "Though the results remain limited and controversial, warranting caution and additional research." Medical marijuana over official looking subscription document. Medical marijuana over official looking subscription document. thegoodphoto/Getty Images The first study looked into patients receiving the immunotherapy drug nivolumab for advanced cancers, including lung cancer, renal cell carcinoma and melanoma. It compared those on nivolumab alone (89 patients) and those on both nivolumab and cannabis (51 patients). The findings, Jansen noted, showed a significantly lower treatment response rate in patients using cannabis than in those on just nivolumab (15.9 vs. 37.5 percent.) The analysis excluded patients with advanced disease with survival of less than two months. "This suggests that patients using cannabis were approximately three times more likely to have a poor response to immunotherapy. Notably, cannabis use did not significantly impact progression-free survival or overall survival," Jansen wrote. Building on this, the second study compared 34 patients prescribed both immunotherapy and cannabis with 68 patients receiving the cancer treatment alone. That study found that tumors tended to take less than three-and-a-half months to grow or spread in the patients taking cannabis, as compared to more than a year for patients on immunotherapy alone. It also found the median overall survival time for cannabis users was 6.4 months compared to 28.5 months for non-users. A colourful illustration representing immune cells and white blood cells. A colourful illustration representing immune cells and white blood cells. quantic69/Getty Images It should be noted that both studies had inherent limitations—including small sample sizes and a focus on inhaled cannabis, rather than the orally-administered versions Jansen notes is favored in his experience with patients. Jansen added: "Factors such as smoking and other lifestyle elements, which heavily influence cancer risk and treatment outcomes, should be carefully considered when assessing cannabis' role in immunotherapy efficacy and cancer progression, and when interpreting the studies." The third study looked at 105 patients with tumors developing in solid organs—e.g. the breast, lung or prostate—receiving immune checkpoint inhibitors, and cannabis use primarily in the form of prescribed dronabinol. (Immune checkpoint inhibitors are a form of immunotherapy treatment that works by blocking proteins that prevent the immune system from attacking cancer cells.) Cannabis use was associated with significantly worse outcomes in patients receiving immunotherapy, including a shorter median overall survival time (6.7 vs 17.3 months), a reduced progression-free survival tune (4.8 vs 9.7 months) and a markedly lower disease control rate (10.7 percent vs 37.7 percent) compared with non-users. "Notably, these negative outcomes were most evident in white patients, raising the possibility of ethnicity-related pharmacogenetic variability in cannabinoid metabolism or immune response," Jansen wrote. Other potentially important factors like performance status, comorbidities and socio-economic status may have also been unaccounted for, and though tobacco was more common among cannabis users, it may still have influenced outcomes. Dropper with medical cannabis CBD hemp oil for oral use. Dropper with medical cannabis CBD hemp oil for oral use. 24K-Production/Getty Images "One of the challenges in interpreting these studies is the inherent complexity of cannabis as a therapeutic agent," wrote Jansen. Past research, Jansen notes, has found that cannabis can suppress the immune system through its active compounds: CBD, THC and other minor cannabinoids. At the same time, however, studies undertaken both in vitro and in living organisms have suggested that cannabinoids can both kill cancer cells and stop from spreading. "These findings hold particular relevance for patients considering, or currently using, medical cannabis during immunotherapy," the doctor said. "As medical practitioners, we must weigh the benefits of cannabis in managing cancer-related symptoms (such as pain, nausea and anorexia) against its potential to compromise treatment efficacy." "While cancer has a promising role in supportive cancer care, these early findings support careful consideration when patients are concurrently undergoing immunotherapy." Jansen emphasized how important it is that clinicians ensure patients are well informed of potential interactions, particularly until we have a clearer understanding of the situation, and has called for more thorough research and trials. "Future studies should aim to control for variables such as cancer type, cannabis dosage, socio-economic status and patient lifestyle factors, particularly tobacco use, which may confound results," he concluded. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about cancer? Let us know via health@ References Bar-Sela, G., Cohen, I., Campisi-Pinto, S., Lewitus, G. M., Oz-Ari, L., Jehassi, A., Peer, A., Turgeman, I., Vernicova, O., Berman, P., Wollner, M., Moskovitz, M., & Meiri, D. (2020). Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers, 12(9), Article 9. Hadid, T., Biedny, A., Mamdani, H., Azmi, A., Kim, S., Jang, H., Uprety, D., Al Hallak, M. N., & Sukari, A. (2024). Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors. Therapeutic Advances in Vaccines and Immunotherapy, 12, 25151355241309095. Jansen, B. (2025). Are cannabinoids with cancer immunotherapy contributing to early death? A call for caution and further study. New Zealand Medical Journal, 138(1619). Taha, T., Meiri, D., Talhamy, S., Wollner, M., Peer, A., & Bar‐Sela, G. (2019). Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. The Oncologist, 24(4), 549–554.


Business Wire
3 days ago
- Business Wire
Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces its entry into the Australian market by signing a new exclusive distribution agreement with Endotherapeutics Pty Ltd, a leading Australia-based distributor of cutting-edge medical devices, to bring the Cellvizio platform to Australian physicians. This strategic expansion comes as Mauna Kea experiences growing momentum for its CellTolerance application, prompting the company to open new geographic markets with strong growth potential. The three-year agreement grants Endotherapeutics the exclusive rights to distribute and promote the Cellvizio platform in Australia. As part of the market entry, a submission for Therapeutic Goods Administration (TGA) approval for the latest generation of Cellvizio products is underway. Mauna Kea Technologies has already been granted TGA clearance in the past and does not anticipate any hurdles in obtaining it again. The partnership will leverage the upcoming launch of the CellTolerance program with Professor Gerald Holtmann, MD, PhD, MBA, a leading Australian physician at Princess Alexandra Hospital in Brisbane, who is planning to acquire one Cellvizio for food intolerance applications. 'This technology brings hope of change for millions of patients suffering from food-related IBS symptoms,' commented Professor Holtmann. 'Cellvizio is truly unique in its ability to help identify the root causes of patient symptoms, enabling the creation of tailored diets. My entire team is excited to explore its full potential and improve the lives of our patients.' 'We're very pleased to partner with Mauna Kea Technologies to introduce Cellvizio to the vibrant Australian GI market,' stated Rob Curtin, Business Manager for GI at Endotherapeutics. 'The potential for Cellvizio and its key indications, particularly pancreatic cyst characterization and food intolerance detection is very significant.' Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies, added: "We are thrilled to partner with Endotherapeutics, a premier distributor of cutting-edge medical devices and a trusted partner with deep roots in the Australian healthcare system. This partnership marks a key milestone in our international expansion strategy. As we see good momentum in the adoption of our platform, particularly for CellTolerance, we are taking key initiatives to expand our market reach in territories with strong growth potential.' *** About Endotherapeutics Pty Ltd Endotherapeutics is a leading Healthcare Technologies distributor serving customers across Australia and New Zealand, headquartered in Sydney, Australia. Endotherapeutics' mission is to improve healthcare and achieves this by supplying innovative healthcare solutions with the highest levels of service and support. To find out more, visit About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.